Professor Lewis is a molecular pharmacologist interested in discovering new venom peptides and ciguatoxins and determining how they interact with the membrane proteins they target using advanced biochemical and spectroscopic methods. Peptides of interest are then modified to improve potency and selectivity. Those with appropriate properties are patented and developed for clinical applications using approaches successfully applied to Xen2174, a conopeptide analogue I co-discovered that is now in ....Professor Lewis is a molecular pharmacologist interested in discovering new venom peptides and ciguatoxins and determining how they interact with the membrane proteins they target using advanced biochemical and spectroscopic methods. Peptides of interest are then modified to improve potency and selectivity. Those with appropriate properties are patented and developed for clinical applications using approaches successfully applied to Xen2174, a conopeptide analogue I co-discovered that is now in Phase II clinical trials for severe pain.Read moreRead less
Venoms To Drugs: Translating Venom Peptides Into Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$751,854.00
Summary
Chronic pain is a major global health problem that currently affects over three million Australians. There are few drugs available for treating chronic pain and many have significant side-effects. Several ion channels are critical for conducting pain signals to the brain. Blocking these channels can provide pain relief and, in some cases, protection from brain injury following stroke. We are producing potent and selective blockers of these ion channels for the treatment of chronic pain and strok ....Chronic pain is a major global health problem that currently affects over three million Australians. There are few drugs available for treating chronic pain and many have significant side-effects. Several ion channels are critical for conducting pain signals to the brain. Blocking these channels can provide pain relief and, in some cases, protection from brain injury following stroke. We are producing potent and selective blockers of these ion channels for the treatment of chronic pain and stroke.Read moreRead less